Treating to Microscopic Healing in IBD: Is It Time to Make Histologic Remission a Treatment Goal?

Table of Contents

• Key Points
• Why This Editorial Matters
• A Decade of Change: How IBD Treatment Goals Have Evolved
• What Is Histologic Remission — and Why Can't We See It?
• The Growing Evidence: Microscopic Healing Predicts Better Outcomes
• The New Swedish Study: Methods and Key Findings
• What the Findings Mean for Crohn's Disease
• Study Limitations: What This Research Cannot Prove
• Practical Questions the Field Must Answer
• What This Means for Patients Today
• Source Information
• Frequently Asked Questions

Key Points

• In a Swedish study of over 63,000 IBD patients, symptom-free people with microscopic inflammation on biopsy had a 42% higher death rate over two years than those in histologic remission.
• Histologic remission means no cellular signs of inflammation under a microscope, going beyond symptom control and endoscopic healing.
• The editorial authors argue doctors should consider making histologic remission a formal treatment goal, alongside symptom control and endoscopic healing.
• In Crohn's disease, the study found higher all-cause and malignancy-related mortality with histologic inflammation, but biopsy sampling protocols are not yet validated.
• The study treated histologic inflammation as present or absent, so it could not show which specific microscopic features most strongly predict risk.

Why This Editorial Matters

Doctors who treat inflammatory bowel disease (IBD, a term covering ulcerative colitis and Crohn's disease) have long used one simple question to judge whether treatment works: "How do you feel?" This editorial argues that the time has come to ask a deeper question as well: "Has the inflammation actually gone away — even at the microscopic level?"

The editorial, written by Dr. David T. Rubin and Dr. Navneet K. Natt of the University of Chicago Medicine, appears in the May 2026 issue of Clinical Gastroenterology and Hepatology. It accompanies a large new nationwide study from Sweden that links persistent microscopic bowel inflammation to higher death rates.

The central message is direct. Chronic inflammation remains dangerous even when symptoms are fully controlled. That principle, the authors say, should reshape patient counseling, treatment discussions, monitoring strategies, and long-term maintenance planning.

A Decade of Change: How IBD Treatment Goals Have Evolved

Over the past decade, treatment targets in IBD have advanced substantially. The driving force: doctors now recognize that symptom control alone is an insufficient benchmark for long-term success.

STRIDE II, an international initiative led by the International Organization for the Study of IBD (IOIBD), laid out a modern framework. It pairs symptom relief with objective assessment. That means measuring inflammation through biochemical tests (blood or stool markers), endoscopic examination (a camera looking at the bowel lining), and radiologic imaging (scans that reveal inflammation deeper in the tissue).

The overall goal goes beyond comfort. The aim is restored quality of life backed by measurable evidence that the disease is actually quiet. In ulcerative colitis (UC, the form of IBD that affects only the large intestine), one additional target has steadily gained attention: histopathological remission, often called histologic remission.

Here is the key distinction doctors now make. Clinical remission means the patient has no symptoms. Endoscopic remission means the lining of the bowel looks healed when a specialist inspects it with a scope. Histologic remission goes one step further. It means that when a small tissue sample (biopsy) is examined under a microscope, the cellular signs of inflammation have disappeared.

What Is Histologic Remission — and Why Can't We See It?

Imagine a house that looks clean on the outside but still has mold growing inside the walls. That analogy helps explain histologic inflammation in IBD. Patients can feel great, and their colon can even look normal during a colonoscopy — yet a biopsy may still reveal active inflammation at the microscopic level.

This distinction is crucial because the bowel can appear pink and smooth to the naked eye while harboring inflammatory cells that a pathologist can easily identify under a microscope. Those cells include neutrophil infiltrates (white blood cells invading the tissue), cryptitis (inflammation of the colonic glands), crypt abscesses (pockets of pus within those glands), erosions, and ulcers.

In ulcerative colitis, histologic remission has not yet been adopted as a formal treatment target. The biology, however, points strongly toward its importance. Microscopic inflammation has long been tied to symptoms and to neoplasia — a medical term for abnormal cell growth that can progress to cancer. The accumulating evidence suggests that erasing microscopic inflammation may be the deepest form of disease control, and it might protect patients from the worst long-term outcomes.

Microscopic assessment in Crohn's disease is harder. Crohn's inflammation is often patchy, skipping segments of bowel, and researchers have not yet validated a standard sampling protocol. Still, the authors stress that these challenges call for more research, not for dismissing the endpoint altogether.

The Growing Evidence: Microscopic Healing Predicts Better Outcomes

The case for treating to histologic remission rests on a broad and growing evidence base. Prior research, much of it cited in this editorial, has shown that the absence of histologic inflammation correlates with several meaningful benefits:

• Lower risk of relapse (disease flare-ups)
• Lower exposure to corticosteroids (steroids)
• Fewer hospitalizations
• Lower risk of neoplasia (pre-cancerous or cancerous changes)
• Fewer surgeries

Newer nationwide population studies have linked persistent histologic activity to consequences far beyond the gut. These include serious infections, reduced fertility in women, and adverse pregnancy outcomes. In other words, active microscopic inflammation appears to affect the whole body, not just the digestive tract.

When histologic remission is combined with clinical and endoscopic improvement, the degree of disease control appears even deeper. Studies describe this combined state as "disease clearance." Patients who achieve it have reduced rates of hospitalization and bowel surgery compared with patients who only feel better.

Recent phase III trials — the large, late-stage studies required for drug approval — reinforce these observations. Advanced therapies (newer biologic and targeted drugs) have now been shown to achieve histo-endoscopic improvement and remission, meaning healing at both the microscopic and scope-visible levels. These trials include:

• The QUASAR program, which tested guselkumab in patients with moderately to severely active ulcerative colitis and reported results in The Lancet in 2025.
• The VIVID study, which tested mirikizumab in patients with moderately to severely active Crohn's disease and published its results in The Lancet in 2024.
• A network meta-analysis by Estevinho and colleagues (2024), which pooled trials of advanced therapies in ulcerative colitis and found consistent evidence of histologic and histo-endoscopic improvement and remission.

Given this momentum, the editorial argues that the central question is shifting. The debate is no longer about whether histologic remission is relevant. Instead, the real question is how — and whether — it should change daily clinical decisions.

The New Swedish Study: Methods and Key Findings

Into this debate comes the study that prompted the editorial: a nationwide cohort study by Sun, Mårild, Bergman, and colleagues, published in the same issue of Clinical Gastroenterology and Hepatology (2026;24:1384–1392).

The researchers used the Swedish population-based registry, a national database that tracks health outcomes across virtually the entire Swedish population. The scale is remarkable: more than 63,000 patients with IBD and histologic data, with records spanning nearly 50 years.

The study examined the relationship between histologic activity — microscopic inflammation found on biopsy — and 2-year all-cause mortality (death from any cause within two years of the biopsy). The design was longitudinal, meaning the researchers followed patients forward in time to observe what happened to them.

The key findings were sobering:

• The presence of either histologic or clinical activity was associated with increased mortality.
• Even among patients who were clinically quiescent (feeling well, with no symptoms), histologic inflammation still conferred an elevated risk of death.
• That elevated risk was quantified as an adjusted hazard ratio of 1.42 (95% confidence interval, 1.08–1.87).

Here is what those numbers mean in plain language. A hazard ratio compares the rate of an event between two groups. A ratio of 1.42 means that, over the study period, patients with silent microscopic inflammation died at a rate 42% higher than similar patients whose biopsies showed remission. "Adjusted" means the researchers accounted for other factors that could influence mortality, so the 42% figure reflects the independent association of histologic inflammation itself.

The 95% confidence interval (1.08–1.87) tells us how precise that estimate is. It means that, based on the data, the true increase in risk is very likely somewhere between 8% and 87% higher. Because the entire interval sits above 1.0 — the value that would mean no increased risk — the finding is statistically significant. In practical terms, there is strong evidence the effect is real, though the exact magnitude remains uncertain.

The editorial authors note that the study benefits from two major strengths. First is the enormous sample size — over 63,000 patients with histologic data. Second is the longitudinal design, which allowed the researchers to observe meaningful improvements in disease control over time.

Yet one finding gives pause. Even with decades of progress and the development of new therapeutic options, a substantial proportion of patients in this modern-era dataset continued to show persistent histologic activity. This raises uncomfortable questions about attainability. Can histologic remission be achieved at a population level, across real-world clinics, not just in carefully controlled trials?

It also highlights a broader implementation gap. Medical advances matter little if they are not translated consistently across diverse practice settings. If histologic remission becomes a target, clinics will need standardized biopsy protocols, reliable pathology reporting, and systems to act on the results.

What the Findings Mean for Crohn's Disease

The Crohn's disease findings deserve particular attention. Sun and colleagues observed higher all-cause mortality and higher malignancy-related mortality (death related to cancer) in patients with histologic inflammation compared with patients in histologic remission.

The malignancy association is especially striking because it appeared specifically in Crohn's disease. A malignancy is a cancer or a growth that can become cancerous.

However, histologic assessment in Crohn's disease is complicated. Crohn's inflammation is patchy — some segments of bowel are inflamed while neighboring segments are normal. Researchers also lack validated sampling protocols for Crohn's disease, meaning there is no universally agreed-upon method for where and how often to take biopsies.

In addition, the editorial notes, there is limited information about whether current therapies can truly induce microscopic healing in Crohn's disease. Most drug trials in Crohn's have focused on symptom relief and endoscopic healing, not histologic endpoints.

These gaps matter. But the authors are explicit: the uncertainty is a reason to fund more research in Crohn's disease, not a reason to abandon the endpoint.

Study Limitations: What This Research Cannot Prove

The authors are careful to flag important caveats in the Swedish study. The first is how the study defined histologic inflammation. The analysis treated microscopic inflammation as a simple yes-or-no category: present or absent.

That dichotomous (two-option) definition, the authors argue, constrains interpretation. It leaves unanswered which specific microscopic features most strongly predict risk. Different findings under the microscope likely carry different prognostic weight:

• Chronic architectural distortion (permanent changes in the shape and structure of the intestinal glands), atrophy (thinning of the tissue), granulomas (clusters of immune cells seen in Crohn's disease), and basal plasmacytosis (accumulations of antibody-producing plasma cells at the base of the mucosa) may reflect long-standing, deeper damage.
• Cryptitis, crypt abscesses, ulcers, and erosions reflect more acute, active inflammation.

These two groups of findings may behave very differently over time. Collapsing them into a single "inflammation present" category hides that nuance. As the field considers making histology an actionable treatment outcome, standardization and granularity — measuring specific features rather than a blanket category — will be critical. The authors point to an ECCO (European Crohn's and Colitis Organisation) position paper by Feakins and colleagues (2024) that works toward precisely such standardized definitions.

The second caveat is intriguing: the Swedish study found no association between histologic inflammation and malignancy-related mortality in ulcerative colitis. This is surprising because the link between histologic inflammation and colorectal neoplasia in UC is well established, including a 2016 systematic review by Colman and Rubin.

How can this discrepancy be explained? The authors offer several possibilities:

• Data limitations within the registry itself.
• Residual confounding — unmeasured factors that distort the relationship.
• The impact of evolving care, including improved medical management, dysplasia surveillance (regular colonoscopies to catch pre-cancerous changes early), and earlier therapeutic intervention.

This last possibility carries a hopeful message: modern care may have disrupted the old pathway from cumulative inflammation to cancer death. Even so, the finding may signal the need to re-examine long-held assumptions about cumulative inflammation and cancer-related mortality, particularly in the current era of aggressive treatment and close monitoring.

Practical Questions the Field Must Answer

Shifting toward histologic treatment targets raises practical considerations that require consensus among specialists. The authors lay out several unresolved questions:

1. How should histologic healing be defined, measured, and interpreted? Standardized scoring systems and biopsy protocols will need broad agreement.
2. What is the expected sequence of improvement? Does histologic healing lag behind symptom relief and mucosal (endoscopic) healing? If so, by how much?
3. What should doctors do when histologic remission is not achieved? What incremental benefit does the patient gain from dose optimization (increasing the dose of the current drug), combination therapy (adding a second drug), or mechanistic switching (changing to a drug with a different way of working)?
4. Which long-term outcomes are we actually trying to modify? Candidates include colectomy (surgical removal of the colon), neoplasia, extraintestinal complications (disease effects outside the digestive tract), and mortality itself.

These are not abstract academic puzzles. They are the practical questions doctors will face in clinic once they have a biopsy result showing microscopic inflammation in a patient who feels fine.

The editorial notes that answering them will require additional data, refined definitions, and clarity about feasibility at scale. One ongoing effort, the VERDICT trial (a randomized controlled trial protocol published by Jairath and colleagues in 2024), is specifically designed to determine the optimal treatment target in ulcerative colitis. Its results, when available, should help clarify how aggressively doctors should treat to achieve deep remission.

What This Means for Patients Today

For patients living with IBD, this editorial delivers several practical takeaways.

First, feeling well is not the same as being well. Symptom control remains essential — no one wants to suffer daily urgency, bleeding, or pain. But the Swedish data reinforce that hidden microscopic inflammation carries real consequences, including a higher risk of death over two years, even among patients who feel perfectly fine.

Second, biopsy results matter, not just how you feel. When your doctor recommends a colonoscopy with biopsies during a period when you feel well, the sample analysis is not busywork. In the context of this new evidence, those microscopic findings may carry information about your long-term trajectory that your symptoms cannot reveal.

Third, don't be surprised if your doctor raises the bar. Treatment discussions may shift from "Are your symptoms controlled?" to "Is your inflammation actually gone?" This may mean more frequent monitoring, more biopsies, or conversations about escalating therapy even when you feel fine.

Fourth, treat decisions as a partnership. The evidence increasingly supports chasing deeper remission, but every treatment adjustment carries its own risks, costs, and burdens. The authors emphasize the importance of balancing achievable gains against risk and cost. Ask your doctor directly: "What would my biopsy results change about my treatment plan, and what is the evidence that changing it will improve my long-term outcome?"

Fifth, the direction of travel is clear. As treatments improve and medical understanding of inflammatory burden expands, histology is likely to play a more explicit role in treatment decisions. The authors conclude that deeper disease control is both biologically relevant and increasingly achievable. It will help shape the next generation of treatment targets in IBD.

None of this means every patient needs to chase a perfect biopsy at any cost. It means that the medical community is moving toward a more complete definition of remission — one that includes microscopic healing as a central piece — and patients should understand that shift as it enters routine care.

Frequently Asked Questions

I feel completely fine. Why would my doctor want to check my gut under a microscope?

Feeling well does not always mean inflammation is gone. In a Swedish study of over 63,000 patients with IBD, symptom-free people who still had microscopic inflammation on biopsy had a 42% higher death rate over two years than those in histologic remission. Biopsies can reveal inflammation your symptoms cannot.

What exactly is histologic remission?

Histologic remission means that when a small tissue sample from your bowel is examined under a microscope, the cellular signs of inflammation have disappeared. It goes beyond clinical remission (no symptoms) and endoscopic remission (the bowel lining looks healed during a scope). It is the deepest level of healing currently described.

What does a hazard ratio of 1.42 mean for me?

A hazard ratio compares event rates between two groups. A ratio of 1.42 means that, over the study period, patients with silent microscopic inflammation died at a rate 42% higher than similar patients whose biopsies showed remission. The 95% confidence interval was 1.08 to 1.87, so the finding was statistically significant.

Does this apply to Crohn's disease as well as ulcerative colitis?

The Swedish study found higher all-cause and malignancy-related mortality in Crohn's disease patients with histologic inflammation compared with those in histologic remission. However, Crohn's inflammation is patchy, and there are no validated biopsy sampling protocols. The editorial authors say this uncertainty calls for more research, not for dismissing the endpoint.

If I have microscopic inflammation, will my treatment change?

Possibly. The editorial argues that doctors should consider making histologic remission a formal treatment goal alongside symptom control and endoscopic healing. That may mean more frequent monitoring, more biopsies, or discussions about escalating therapy even when you feel fine. Every adjustment carries its own risks, costs, and burdens, so decisions should be a partnership.

What are the limitations of the Swedish study?

The study treated histologic inflammation as a simple yes-or-no category, so it could not show which specific microscopic features most strongly predict risk. It also found no link between histologic inflammation and malignancy-related mortality in ulcerative colitis, which was surprising. Registry data limitations and unmeasured factors may have influenced results.

What should I ask my doctor about my biopsy results?

Ask directly: "What would my biopsy results change about my treatment plan, and what is the evidence that changing it will improve my long-term outcome?" The editorial emphasizes balancing achievable gains against risk and cost. Treatment decisions should be a partnership, especially when considering deeper remission targets.

If my IBD symptoms are controlled but my biopsy still shows microscopic inflammation, when should I seek a second opinion?

When symptoms are controlled but a biopsy still shows microscopic inflammation, a second opinion can help clarify what that finding means for your treatment plan. Persistent histologic activity has been linked to a 42% higher death rate over two years, even in symptom-free patients, and to relapse, hospitalization, surgery, and cancer risk. A second review can address whether your biopsy was interpreted consistently, whether deeper remission is achievable, and what monitoring or therapy changes are reasonable. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article: "Is It Time to Treat to Histologic Remission Yet?" — an editorial by David T. Rubin, MD, and Navneet K. Natt, MD, of the Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois.

Publication details: Clinical Gastroenterology and Hepatology, 2026;24:1234–1235. The editorial accompanies the study "Histologic Remission and Mortality in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study" by Sun J, Mårild K, Bergman D, et al., published in the same journal (2026;24:1384–1392).

Disclosures: Dr. Rubin has received grant support from Pfizer and Takeda and serves as a consultant for numerous pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Eli Lilly, Genentech (Roche), and others. Dr. Natt has no conflicts of interest to disclose. This article is noted as the "most current article" on the topic at the time of publication.

This patient-friendly article is based on peer-reviewed research. It has been written for an educated patient audience and is not a substitute for individualized medical advice from your own gastroenterologist.